Lavinia Salama, PharmD, joins Craig Beavers, PharmD, to discuss implementing the 2026 CKM guidelines in clinical practice.

Craig Beavers, PharmD, shares his initial thoughts on the new 2026 CKM guidelines, which highlights a landmark shift in cardiovascular care.

Craig Beavers highlights 3 major developments in cardiovascular and cardiometabolic medicine that pharmacists should have on their radar.

Rhonda Monroe discusses her harrowing journey as a 3-time heart attack and stroke survivor, highlighting the critical importance of patient self-advocacy.

Pharmacists' role in lipid management takes center stage with the 2026 dyslipidemia guideline update.

Explore how pharmacists elevate electrophysiology care and get a preview of ACC 2026 trials on AF, HFpEF, pulmonary embolism, and hypertension.

Allison Burnett, PharmD, joins The Tell-Tale Heart to break down the first-ever ACC/AHA acute pulmonary embolism guidelines.

Craig Beavers, PharmD, explores new phase 3 evidence on factor XIa inhibitors for secondary stroke prevention, highlighting OCEANIC-STROKE results, safety, and patient selection.

Host Craig Beavers explores why US blood pressure control still lags despite proven treatments.

Craig Beavers is joined by the investigators of the POLY-HF trial to reinforce the critical role of pharmacist counseling and education in treating patients with heart failure.

In this episode, we break down the genetics, diagnosis, and clinical impact of HCM, explore how management strategies have evolved, and discuss the emerging role of cardiac myosin inhibitors in treating obstructive disease.

Host Craig Beavers sits down with Marc Baines, cofounder and executive director of the HeartLife Foundation, to explore heart failure care through the lens of lived experience.

Craig Beavers and Kyle Fischer, PharmD, BCCP, MBA, discuss key late-breaking cardiovascular trials expected at the American Heart Association’s upcoming annual meeting, exploring their clinical relevance and implications for pharmacists.

Prior to the 2025 American Heart Association (AHA) Scientific Sessions Meeting, Craig J. Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS (AQ-Cardiology), CACP, discusses two recent papers that are influencing practice within the cardiovascular space.

Craig Beavers discusses recent developments in hypertension management and the clinical implications of the Bax Hypertension and KARDIA-3 trials with Shelby Tungate from the UNC Eshelman School of Pharmacy.

Host Craig Beavers discusses the validity of meta-analyses and highlights analyses from European Society of Cardiology (ESC) 2025 with Bill Baker, PharmD, FCCP, FACC, FAHA.

Host Craig Beavers sits down with Lorenz van der Linden, a Belgian pharmacist, to dive deep into 2 groundbreaking trials from the European Society of Cardiology (ESC) 2025 Congress.

Following the European Society of Cardiology Congress 2025, experts gathered to discuss key Hot Line trial data.

Experts discuss groundbreaking Hot Line trials at the European Society of Cardiology Congress 2025, offering insights into the latest cardiovascular research.

The COBBRA trial compared bleeding risk with rivaroxaban vs apixaban in patients with acute venous thromboembolism.

Host Craig Beavers sits down with Kazuhiko Kido, PharmD, a clinical associate professor at the West Virginia University School of Pharmacy, to discuss intravenous iron and its use in patients with heart failure.

Host Craig Beavers chats with Shannon Finks, PharmD, FCCP, BCPS, BCCP, AHSCP-CHC, president and director of pharmacy services at ZupMed in Memphis, Tennessee.

Ralph Riello, PharmD, BCPS, a board-certified clinical pharmacy specialist at the Yale University School of Medicine, discusses challenges in implementation for novel cardiovascular treatments and interventions.

Host Craig Beavers speaks with Orly Vardeny, PharmD, MS, a professor of medicine at the University of Minnesota

Host Craig Beavers spoke with Arthur Allen, PharmD, for the latest updates from the RIVAWAR trial and the newest ACS guidelines.